Invivyd completes enrollment in Phase 3 LIBERTY trial of VYD2311 antibody vs mRNA COVID vaccine

Invivyd

Invivyd

IVVD

0.00
  • Invivyd completed enrollment in its Phase 3 LIBERTY trial comparing VYD2311 antibody prophylaxis with an mRNA COVID-19 vaccine.
  • Topline results have not been presented; initial data are expected in Q3 2026, potentially alongside the pivotal DECLARATION readout.
  • The study aims to show whether VYD2311 delivers better tolerability than vaccination, supporting positioning as a vaccine alternative if cleared.
  • LIBERTY also evaluates safety when VYD2311 is given with an mRNA vaccine, informing real-world use and regulatory discussions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160701PRIMZONEFULLFEED9747364) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.